Combination Of Viral And Bacterial Antigens (e.g., Multivalent Viral And Bacterial Vaccine, Etc.) Patents (Class 424/201.1)
-
Publication number: 20110081376Abstract: A method for using inactivated Japanese encephalitis virus particles as an adjuvant of a vaccine is provided. A method for using inactivated Japanese encephalitis virus (JEV) particles as an adjuvant of various vaccines or a mixed vaccine, said JEV particles being obtained by inoculating JEV Beijing-1 strain to Vero cells, culturing said JEV-infected cells to give cultured cells or culture supernatant, purifying JEV particles from said cultured cells or culture supernatant and inactivating said JEV particles with formalin, a method for preparing a (mixed) vaccine which comprises a step of letting inactivated Japanese encephalitis virus be contained, and a mixed vaccine prepared by said method.Type: ApplicationFiled: May 27, 2009Publication date: April 7, 2011Applicant: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTEInventors: Makoto Moriyama, Kazuyoshi Kaminaka, Junichi Matsuda, Chikateru Nozaki
-
Patent number: 7914791Abstract: A method for stimulating the immune response to a vaccine applied to a mammalian subject includes the step of administering to the subject an effective amount of EtxB or a molecule having substantially equivalent activity, free from whole toxin and not linked to an antigen.Type: GrantFiled: May 10, 1999Date of Patent: March 29, 2011Assignee: Trident Pharmaceuticals, Inc.Inventors: Timothy Raymond Hirst, Neil Andrew Williams, Andrew Morgan, Andrew Douglas Wilson, Lucy Amber Bird
-
Publication number: 20110059126Abstract: The present invention provides methods of reducing the vircidal activity of a composition comprising a PCV-2 antigen as well as antigenic preparations and immunogenic compositions comprising a PCV-2 antigen, wherein the virucidal activity has been reduced. In addition, the present invention also relates to a method of increasing the immunogenicity of an immunogenic composition comprising a PCV-2 antigen as well as immunogenic composition with an increased immunogenicity.Type: ApplicationFiled: September 2, 2010Publication date: March 10, 2011Applicant: Boehringer Ingelheim Vetmedica, Inc.Inventors: Caroline Ann Kohler, Guosong Zhao, Ali Khazraeinazmpour, Bernd Colin Eichenmueller, Marc Allan Eichmeyer, Gregory Haiwick, Merrill Lynn Schaeffer
-
Publication number: 20110045017Abstract: This invention is directed to pharmaceutical compositions comprising an HIV antigen and a mucosal adjuvant and methods for raising an immune response in a subject by administering these compositions. Preferably, the pharmaceutical compositions of the invention can be used to treat or prevent HIV infection.Type: ApplicationFiled: November 8, 2010Publication date: February 24, 2011Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.Inventors: YING LIAN, JAN ZUR MEGEDE, INDRESH SRIVASTAVA, SUSAN W. BARNETT
-
Publication number: 20110033496Abstract: The present invention pertains to the use of a non-live carbohydrate containing composition, the carbohydrate being also found in live Lawsonia intracellularis cells in association with the outer cell membrane of these cells, for the manufacture of a vaccine for protection against an infection with Lawsonia intracellularis, the vaccine being in a form suitable for systemic administration.Type: ApplicationFiled: April 16, 2009Publication date: February 10, 2011Inventors: Antonius Arnoldus Christiaan Jacobs, Paul Vermeij, Ruud Philip Antoon Maria Segers, Carla Christina Schrier
-
Publication number: 20110033448Abstract: Methods and compositions for treating disease are provided. More particularly, methods and compositions of inhibiting pathogenic interferon production are prevented, which may be useful in the treatment of various diseases. In other embodiments, therapeutic compounds and methods for the treatment of autoimmune diseases and chronic inflammatory diseases are provided. One such method is a method for inhibiting pathogenic interferon production or inhibiting activation of plasmacytoid dendritic cells or treating an autoimmune or chronic inflammatory disease, which comprises inhibiting one or more of LL-37 and hCAP18.Type: ApplicationFiled: December 17, 2007Publication date: February 10, 2011Inventors: Michel Gilliet, Roberto Lande, Yong-Jun Liu
-
Publication number: 20110033495Abstract: The present invention relates to the use of an immunogenic composition that comprises a PCV2 antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with an enteric infection, even more preferably, with enteric disease. The use relates to a method comprising the steps of administering the composition to an animal in need thereof, preferably prior to disease exposure. Administration of PCV2 antigen, preferably ORF2 of PCV2, lessens the incidence and reduces the severity of the enteric disease.Type: ApplicationFiled: February 14, 2009Publication date: February 10, 2011Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventors: Michael Roof, Marc Eichmeyer
-
Publication number: 20110033497Abstract: The present invention pertains to a vaccine comprising in combination non-live antigens of Lawsonia intracellularis, of Mycoplasma hyopneumniae and Porcine circo virus, and a pharmaceutically acceptable carrier. The invention also pertains to a kit comprising a first container having contained therein non-live antigens of Lawsonia intracellularis, one or more other containers having contained therein Mycoplasma hyopneumoniae and Porcine circo virus antigens and instructions for mixing the antigens of Lawsonia intracellularis, Mycoplasma hyopneumoniae, and Porcine circo virus to formulate one combination vaccine suitable for systemic vaccination.Type: ApplicationFiled: April 16, 2009Publication date: February 10, 2011Inventors: Antonius Arnoldus Christiaan Jacobs, Paul Vermeij, Ruud Philip Antoon Maria Segers, Carla Christina Schrier
-
Patent number: 7879336Abstract: The present invention relates to providing new vaccines and treatments for the diseases related to canine influenza virus. It discloses influenza viral antigens, and methods of presenting these antigens to canines, especially dogs. It relates to attenuated and killed vaccines. The present invention relates to experimentally generated canine and equine influenza viruses. invention also includes influenza A, including H3, N8, H3N8, H7N7 and viruses which contain at least one genome segment from an canine or equine influenza virus. The present invention also relates to the use of these viruses in therapeutic compositions to protect canines, dogs in particular, from diseases caused by influenza viruses.Type: GrantFiled: June 23, 2008Date of Patent: February 1, 2011Assignee: Pharmacia & Upjohn Company, LLCInventors: Shelly L. Shields, Hans A Draayer, Michael J Huether
-
Publication number: 20110020392Abstract: The present invention provides a composition and method for treating diseases associated with demyelination of the nerves, such as RA, Tremors/Parkinson's Disease, and MS, and for treating non-viral based cancers. By administering measured doses of an immunity-provoking agent and a bacterial antigen activator, patients suffering from RA, MS, Tremors/Parkinson's Disease, and prostrate cancer realized immediate beneficial results with no side effects.Type: ApplicationFiled: October 14, 2008Publication date: January 27, 2011Applicant: Salubrious Pharmaceutical, LLCInventor: George Nelson
-
Publication number: 20110020393Abstract: The present inventors improved methods for inactivating Japanese encephalitis virus vaccines, and assessed the safety of vaccines produced by combining multiple vaccines. The present inventors successfully produced safer Japanese encephalitis vaccines by cell culture, which can be stored more stably over a long period than conventional Japanese encephalitis vaccines. Furthermore, it is also expected that the production methods can be used to produce other viral vaccines with excellent storage stability.Type: ApplicationFiled: December 26, 2008Publication date: January 27, 2011Inventors: Tomoyoshi Komiya, Hiroko Toriniwa
-
Patent number: 7871625Abstract: Modified HCV multiple epitope fusion antigens (MEFAs) are described. The proteins include modified sequences such that proteolytic cleavage of the MEFAs by HCV NS3 protease is inhibited. HCV immunoassays including the modified MEFAs are also described.Type: GrantFiled: August 26, 2005Date of Patent: January 18, 2011Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: David Chien, Doris Coit, Carlos George-Nascimento, Sansan Lin, Angelica Medina-Selby, Laura Tandeske
-
Patent number: 7867498Abstract: The invention relates to polypeptide carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are useful as components of vaccines that can elicit a T-cell dependent immune response. These vaccines are particularly useful to confer protection against infection from encapsulated bacteria in infants between the ages of 3 months and about 2 years.Type: GrantFiled: March 25, 2009Date of Patent: January 11, 2011Assignee: Novartis AGInventors: Rino Rappuoli, Guido Grandi
-
Publication number: 20100330117Abstract: The present invention provides a composition and method for treating diseases associated with demyelination of the nerves, such as ALS, RA, Tremors/Parkinson's Disease, and MS, Alzheimer's disease, ALS, Guillain-Barre syndrome, atherosclerosis, schizophrenia, Tremors/Parkinsons's disease, senile dementia, Muscular Dystrophy, Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, Complex Regional Pain Syndrome, Diabetes, Neuropathic Pain, Spider Arthritis West Nile Virus, Fibromyalgia, Shingles, Gout, Migraine Headaches, Post Polio Syndrome, Central Virus Deafness, Asthma, Chronic Pain Of Unknown Origin and Hepatitis C and for treating non-viral based cancers. By administering measured doses of an immunity-provoking agent and a bacterial antigen activator, patients suffering from ALS, RA, MS, Tremors/Parkinson's Disease, and prostate cancer and others realized immediate beneficial results with no side effects.Type: ApplicationFiled: April 13, 2010Publication date: December 30, 2010Applicant: SALUBRIOUS PHARMACEUTICAL, LLCInventor: George Nelson
-
Patent number: 7858100Abstract: The present invention relates to a novel rod-shaped pleiomorphic non-motile Gram-negative bacterium causing a new, deadly, disease in fish, to a microbiological culture comprising said bacterium, to a vaccine comprising said bacterium and methods for the preparation of such a vaccine, to antibodies reactive with said bacterium, to diagnostic test kits and to the use of said bacterium.Type: GrantFiled: November 9, 2006Date of Patent: December 28, 2010Assignee: Intervet International B.V.Inventor: Are Nylund
-
Publication number: 20100316665Abstract: An antigen-presenting system (APS) comprising one or more enterobacterial antigens in combination with a papaya mosaic virus (PapMV) or a virus like particle (VLP) derived from papaya mosaic virus is provided. The PapMV or VLP included in the APS is capable of potentiating an immune response against said one or more enterobacterial antigens. The APS can be used, for example, as a vaccine against enterobacterial disease, such as typhoid fever. The one or more antigens comprised by the APS can be conjugated to a coat protein of the PapMV or PapMV VLP, or they may be non-conjugated (i.e. separate from the PapMV or PapMV VLP), or the APS can comprise both conjugated and non-conjugated antigens. Conjugation can be, for example, by genetic fusion with the coat protein, or binding via covalent, non-covalent or affinity means.Type: ApplicationFiled: January 28, 2008Publication date: December 16, 2010Inventors: Denis Leclerc, Constantino Roberto López-Macias, III
-
Patent number: 7833775Abstract: Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and/or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and/or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and/or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases.Type: GrantFiled: February 6, 2004Date of Patent: November 16, 2010Assignee: Aduro BioTechInventors: Thomas W. Dubensky, Jr., Dirk G. Brockstedt, John E. Hearst, David N. Cook
-
Publication number: 20100285057Abstract: Heat treated bacterins, a method of producing heat treated bacterins, and porcine emulsion vaccines prepared from such heat treated bacterins are disclosed.Type: ApplicationFiled: May 7, 2010Publication date: November 11, 2010Applicant: PFIZER INC.Inventors: Mark D. Goodyear, Michael J. Huether, Richard Lee Krebs, Nancee L. Oien
-
Publication number: 20100285055Abstract: The present invention relates to filovirus VLPs and their use in activating innate immunity, specifically natural killer cells, and in enhancing an immune response to an antigen in an animal.Type: ApplicationFiled: March 22, 2010Publication date: November 11, 2010Inventors: Sina Bavari, Kelly L. Warfield
-
Publication number: 20100266628Abstract: An injectable composition, capable of preventing or controlling parasitic, viral, or bacterial infections or diseases, for example scours, in pregnant cows and viral infections or diseases in neonatal calves by parenterally administering to each cow in a herd of pregnant cows, a dose of a combination composition comprising: (a) at least one inactivated viral component derived from rotavirus and/or coronavirus; (b) a macrocyclic lactone active compound; and (c) a pharmaceutically acceptable parenteral carrier and preservative. The injectable compositions which include eprinomectin result in extremely low milk residues.Type: ApplicationFiled: April 13, 2010Publication date: October 21, 2010Inventors: Majid Razzak, Robert Holmes
-
Publication number: 20100266629Abstract: The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PI3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardj-prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo-bovis and Leptospira pomona by administering to the animal an effective amount of a combination vaccine. The combination vaccine can be a whole or partial cell inactivated or modified live preparation.Type: ApplicationFiled: June 22, 2010Publication date: October 21, 2010Applicant: PFIZER INCInventors: Paul J. Dominowski, Michael John Huether, Mark D. Goodyear
-
Publication number: 20100260795Abstract: The invention pertains to a carrier particle comprising a hydrophilic phase containing a micro-organism and/or subunit thereof, the hydrophilic phase being dispersed in a hydrophobic continuous phase being solid at room temperature, wherein the hydrophobic phase is constituted to undergo a solid-to-liquid conversion at a temperature above room temperature, the conversion comprising a first order transition. The invention also pertains to a pharmaceutical composition comprising said particles, a method for preparation the pharmaceutical composition and the use of this composition in the treatment of an animal.Type: ApplicationFiled: November 26, 2008Publication date: October 14, 2010Inventors: Erwin Mombarg, Rogier Biemans
-
Patent number: 7811583Abstract: The present invention discloses novel proteins, e.g., antigens, from Piscirickettsia salmonis. The present invention further discloses nucleic acids that encode these proteins. The present invention also discloses the use of the proteins, e.g., antigens, and nucleic acids to prepare vaccines against salmonid rickettsial septicemia (SRS). The present invention also discloses vaccines that can be used to protect fish from Piscirickettsia salmonis, as well as other pathogens. In addition, the present invention discloses methods of using the vaccines of the present invention to protect fish from SRS as well as from other pathogenic diseases.Type: GrantFiled: December 18, 2008Date of Patent: October 12, 2010Assignee: Intervet International B.V.Inventors: David Francis Kirke, Michael James Francis
-
Publication number: 20100233205Abstract: Compositions comprising a Neisserial antigen and a detoxified ADP-ribosylating toxin are provided. These compositions have been found useful for mucosal immunization, particularly for nasal immunization against Neisseria meningitidis.Type: ApplicationFiled: May 25, 2010Publication date: September 16, 2010Applicant: NOVARTIS VACCINES AND DIAGNOSTICS SRLInventors: Mariagrazia PIZZA, Marzia Monica Guiliani
-
Publication number: 20100233204Abstract: The present disclosure relates to multivalent immunogen compositions for treating or preventing diseases or disorders in canines caused by or associated with one or more of canine distemper virus, canine adenovirus (type 1 or type 2), canine parainfluenza virus, canine parvovirus, Leptospira canicola, Leptospira icterohaemorrhagiae, Leptospira grippotyphosa, Leptospira pomona, Leptospira bratislava, Leptospira hardjo, Leptospira autumnalis, Leptospira australis, Leptospira hebdomadis, and Bordetella bronchiseptica. The Leptospira compositions can also be used for treating or preventing leptospirosis diseases or disorders in canine, swine, and bovine.Type: ApplicationFiled: February 25, 2008Publication date: September 16, 2010Applicant: WYETHInventor: Michael Alonzo Gill
-
Patent number: 7794735Abstract: The invention belongs to the field of animal health and in particular the causative agent of a new bacterial poultry disease, Gallibacterium. The invention provides said Gallibacterium bacteria, vaccine comprising inactivated Gallibacterium, and a method of immunizing to prevent disease in poultry.Type: GrantFiled: February 25, 2009Date of Patent: September 14, 2010Assignee: Boehringer Ingelheim Vetmedica S.A. DE C.V.Inventors: Raul Campogarrido, Carlos Gonzalez-Hernandez, Vaithianathan Sivanandan, Maria Elena Vazquez
-
Publication number: 20100226937Abstract: Processes for preparing combination vaccines that include diphtheria and tetanus toxoids, where these two toxoids are used in the processes as a single component containing both toxoids, and also containing 1-hydroxy-2-phenoxyethane.Type: ApplicationFiled: August 15, 2007Publication date: September 9, 2010Applicant: NOVARTIS AGInventor: Mario Contorni
-
Publication number: 20100226934Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection is further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.Type: ApplicationFiled: September 17, 2009Publication date: September 9, 2010Applicant: WYETHInventors: André JESTIN, Emmanuel Albina, Pierre Le Cann, Philippe Blanchard, Evelyne Hutet, Claire Arnauld, Catherine Truong, Dominique Mahe, Roland Cariolet, François Madec
-
Publication number: 20100221275Abstract: This invention involves compositions and methods for protecting animals from pestivirus infection and for treating animals infected with pestivirus. Pharmaceutical compositions containing E2 and NS3 from a pestivirus are used to protect animals or treat animals.Type: ApplicationFiled: October 28, 2008Publication date: September 2, 2010Applicant: Novartis AGInventors: Joe Brownlie, Margaret Collins, Carole Thomas, Ian Thompson
-
Patent number: 7785570Abstract: The present invention relates to a combination vaccine for the protection of poultry against Ornithobacterium rhinotracheale, to the use of a live over-attenuated Ornithobacterium rhinotracheale strain and a live attenuated poultry virus for the manufacturing of such a combination vaccine, to methods for the preparation of said combination vaccine and to vaccination kits for the immunization of poultry against Ornithobacterium rhinotracheale.Type: GrantFiled: December 21, 2004Date of Patent: August 31, 2010Assignee: Internet International B.U.Inventors: Antonius Arnoldus Christiaan Jacobs, Paul Cornelius Maria van Empel, Petrus Johannes Maria Nuijten
-
Patent number: 7785875Abstract: There are provided a polynucleotide encoding HCV epitopes, an immunogenic composition including same, and a method of inducing an HCV-specific immune response using same.Type: GrantFiled: November 3, 2008Date of Patent: August 31, 2010Assignee: Mogam Biotechnology Research InstituteInventors: Yu Kyeong Hwang, Okjae Lim, Hyejin Chung
-
Publication number: 20100215679Abstract: The disclosure provides an antigenic composition useful for immunization against tularemia. The disclosure provides a method for producing a vaccine for preventing tularemia in humans and animals, a new vaccine against tularemia in humans and animals, and a new approach to producing vaccines against tularemia.Type: ApplicationFiled: October 22, 2007Publication date: August 26, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Marcus A. Horwitz, Qingmei Jia, Bai-Yu L. Clemens, Daniel Clemens
-
Patent number: 7776340Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (eg Quebec and LY138) and human coronavirus strain OC43. The CRCV spike, polymerase and hemagglutinin/esterase cDNA and protein partial sequences are listed in FIGS. (1) to (4), (13) and (14).Type: GrantFiled: July 1, 2003Date of Patent: August 17, 2010Assignee: The Royal Veterinary CollegeInventors: John Brownlie, Victoria Jane Chalker, Kerstin Erles
-
Publication number: 20100203137Abstract: A liquid Hib component is used to reconstitute a lyophilised meningococcal component, thereby producing a combined meningitis vaccine. A lyophilised meningococcal component can also be reconstituted with an oil-in-water emulsion.Type: ApplicationFiled: June 4, 2008Publication date: August 12, 2010Inventors: Mario Contorni, Paolo Costantino
-
Publication number: 20100178301Abstract: The present invention relates to combination vaccines for the prophylaxis and treatment of microbiological infections in cattle which comprise an attenuated bovine viral diarrhea virus (BVDV) for the the prophylaxis and treatment of BVDV caused infections. The invention also relates to a method of vaccinating a pregnant cow.Type: ApplicationFiled: January 9, 2009Publication date: July 15, 2010Applicant: Boehringer Ingelheim Vetmedica, Inc.Inventors: Carol L. Rinehart, Craig Jones, Judy Myers-Kuhnhoff, Wayne Cole, William Charles Ohnesorge
-
Patent number: 7754219Abstract: The present invention is directed to a method for delivering exogenous proteins to the cytosol, by binding a target antigen (such as a protein) to a transport factor that contains a fragment of a bipartite protein exotoxin, but not the corresponding protective antigen. Preferably, the target antigen is fused to the transport factor. Preferred transport factors include the protective antigen binding domain of lethal factor (LFn) from B. anthracis, consisting of amino acids 1-255, preferably a fragment of at least 80 amino acids that shows at least 80% homology to LFn, and a fragment of about 105 amino acids from the carboxy portion that does not bind PA. The target antigen can include any molecule for which it would be desirable to elicit a CMI response, including viral antigens and tumor antigens.Type: GrantFiled: March 28, 2002Date of Patent: July 13, 2010Assignees: President and Fellows of Harvard College, The General Hospital CorporationInventors: Yichen Lu, Huyen Cao
-
Patent number: 7749979Abstract: A CpG DNA adjuvant in avian vaccines is disclosed, which includes an immunostimulatory oligodeoxynucleotide (ODN) having a sequence of SEQ ID NO: 2. The CpG DNA adjuvant in avian vaccines is advantageous to carry out large-scale production, specifically enhance avian innate and adaptive immune responses, and the CpG DNA adjuvant is hardly to be digested by DNase due to its particular structures.Type: GrantFiled: October 29, 2008Date of Patent: July 6, 2010Assignee: National Pingtung University of Science and TechnologyInventors: Hso-Chi Chaung, Li-Hsiang Hung, Yi-Yang Lien
-
Publication number: 20100158940Abstract: A process for manufacturing a vaccine, wherein the vaccine comprises diphtheria toxoid and tetanus toxoid and, and wherein the process comprises steps of combining (i) a first bulk comprising diphtheria toxoid and tetanus toxoid with (ii) a second bulk comprising tetanus toxoid but no diphtheria toxoid. This arrangement facilitates convenient manufacture of both pediatric and adolescent vaccines from the same bulks: the first bulk can have a diphtheriartetanus ratio that is suitable for pediatric vaccines, and the second bulk can be used to reduce the relative amount of diphtheria toxoid, as found in the adolescent vaccines.Type: ApplicationFiled: August 15, 2007Publication date: June 24, 2010Applicant: NOVARTIS AGInventor: Eric Frings
-
Publication number: 20100150958Abstract: The invention relates to new vaccine compositions for vaccinating birds.Type: ApplicationFiled: November 18, 2009Publication date: June 17, 2010Applicant: VECTOGEN PTY LTD.Inventor: Michael Sheppard
-
Patent number: 7736658Abstract: This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira Bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona. The vaccines of the present invention include a Bordetella bronchiseptica p68 antigen.Type: GrantFiled: November 20, 2007Date of Patent: June 15, 2010Assignee: Pfizer Inc.Inventors: Paul J. Dominowski, Joseph C. Frantz, Richard L. Krebs, Shelly L. Shields, Robert Greg Sorensen
-
Publication number: 20100143403Abstract: The present invention provides methods of inducing an immune response against Clostridium species in birds, for protecting birds from Clostridium infection, and/or for protecting birds from related disorders such as necrotic enteritis. The methods can be practiced in ovo and/or post-hatch. The invention further provides compositions and methods for delivery of a composition of this invention in ovo directly to the embryo body.Type: ApplicationFiled: November 24, 2009Publication date: June 10, 2010Inventors: Vivian W. Doelling, Rebecca M. Poston, Cherilyn L. Heggen-Peay, Alan P. Avakian
-
Patent number: 7731967Abstract: The invention provides, inter alia, immunogenic compositions comprising a first antigen, at least two adjuvants, wherein a first adjuvant comprises a polymer derived from poly(lactides) and/or poly(lactide-co-glycolides), and wherein a second adjuvant comprises an imidazoquinoline, wherein said first antigen is encapsulated within, adsorbed or conjugated to, co-lyophilized or mixed with said first adjuvant, and a pharmaceutically acceptable excipient, wherein said composition elicits a cellular immune response when administered to a vertebrate subject. The invention also provides methods of producing immunogenic compositions, methods for producing a cytotoxic-T lymphocyte (CTL) response in a vertebrate subject, and methods of immunization.Type: GrantFiled: April 29, 2004Date of Patent: June 8, 2010Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Derek O'Hagan, Manmohan Singh
-
Publication number: 20100136049Abstract: The present invention provides methods of inducing an immune response against Clostridium species in birds, for protecting birds from Clostridium infection, and/or for protecting birds from related disorders such as necrotic enteritis. The methods can be practiced in ovo and/or post-hatch. The invention further provides compositions and methods for delivery of a composition of this invention in ovo directly to the embryo body.Type: ApplicationFiled: November 24, 2009Publication date: June 3, 2010Inventors: VIVIAN W. DOELLING, REBECCA M. POSTON, CHERILYN L. HEGGEN-PEAY, ALAN P. AVAKIAN
-
Patent number: 7718357Abstract: The invention relates to a method for inducing a homologous protection against the 4 dengue serotypes in a patient, comprising the sequential administration, to said patient, (i) of a dose of a vaccinal dengue virus of a first serotype and of a dose of a vaccinal dengue virus of a second serotype, and (ii) of a dose of a vaccinal dengue virus of a third serotype and of a dose of a vaccinal dengue virus of a fourth serotype, in which the vaccinal dengue viruses (ii) are administered at least 30 days and at most 1 year after administration of the vaccinal viruses (i).Type: GrantFiled: July 12, 2007Date of Patent: May 18, 2010Assignee: Sanofi Pasteur SAInventors: Bruno Guy, Véronique Barban, Rémi Forrat, Jean Lang
-
Patent number: 7718358Abstract: The invention relates to a method for inducing a protection against the 4 dengue serotypes in a patient, comprising (a) a first series of administrations (i) of a dose of a vaccinal dengue virus of a first serotype and of a dose of a vaccinal dengue virus of a second serotype, and (ii) of a dose of a vaccinal dengue virus of a third serotype and of a dose of a vaccinal dengue virus of a fourth serotype, and (b) a second series of administrations of doses (i) and (ii), in which the doses (i) and (ii) are administered simultaneously at separate anatomical sites, and in which the second series (b) is implemented at least 30 days to at most 12 months after the first series (a).Type: GrantFiled: October 2, 2007Date of Patent: May 18, 2010Assignee: Sanofi Pasteur SAInventors: Bruno Guy, Remi Forrat, Jean Lang, Veronique Barban
-
Publication number: 20100104594Abstract: The invention belongs to the field of animal health and in particular the causative agent of a new bacterial poultry disease, Gallibacterium. The invention provides said Gallibacterium bacteria, vaccine comprising inactivated Gallibacterium, and a method of immunizing to prevent disease in poultry.Type: ApplicationFiled: August 26, 2009Publication date: April 29, 2010Applicant: BOEHRINGER INGELHEIM VETMEDICA, S.A. DE C.V.Inventors: Raul Campogarrido, Carlos Gonzalez-Hernandez, Vaithianathan Sivanandan, Maria Elena Vazquez
-
Publication number: 20100080823Abstract: Compositions are provided which include hyaluronic acid derivatives in combination with vaccine antigens, and optionally adjuvants, for mucosal delivery. Also provided are methods of making the compositions, as well as methods of immunization using the same.Type: ApplicationFiled: November 10, 2009Publication date: April 1, 2010Inventors: Derek O'Hagan, Alessandra Pavesio
-
Publication number: 20100062017Abstract: The present invention relates to live attenuated bacteria of the species Pasteurella multocida, to live attenuated vaccines comprising such live attenuated bacteria, to the use of such bacteria for the manufacture of such vaccines, to methods for the preparation of such vaccines and to diagnostic tests for the detection of such bacteria.Type: ApplicationFiled: December 21, 2005Publication date: March 11, 2010Applicant: Wim de Korverstraat 35Inventor: Yugang Luo
-
Patent number: 7674469Abstract: This invention is directed to a vaccine and a method for using the vaccine to protect a feline from influenza virus infection. The vaccine comprises one or more antigens from one or more H3, N8, H7 or N7-type influenza viruses.Type: GrantFiled: October 25, 2007Date of Patent: March 9, 2010Assignee: Internet International B.V.Inventors: Nallakannu P. Lakshmanan, Melissa A. Lum, Frank J. Sterner, Frederick Randal Bethke
-
Publication number: 20100055166Abstract: The present invention relates to, inter alia, a method of raising an immune response against a pathogen which comprises administering (i) one or more first immunogenic polypeptides derived from said pathogen; (ii) one or more adenoviral vectors comprising one or more heterologous polynucleotides encoding one or more second immunogenic polypeptides derived from said pathogen; and (iii) an adjuvant; wherein the one or more first immunogenic polypeptides, the one or more adenoviral vectors and the adjuvant are administered concomitantly. The invention also relates to vaccines, pharmaceutical compositions, kits and uses employing said polypeptides, adenoviral vectors and adjuvants.Type: ApplicationFiled: February 28, 2008Publication date: March 4, 2010Inventor: Gerald Hermann Voss